These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 9286770)
1. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. White M; Pelletier GB; Tan A; Jesina C; Carrier M J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770 [TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. van Mourik ID; Thomson M; Kelly DA Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349 [TBL] [Abstract][Full Text] [Related]
3. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413 [TBL] [Abstract][Full Text] [Related]
5. Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection? el Gamel A; Keevil B; Rahman A; Campbell C; Deiraniya A; Yonan N J Heart Lung Transplant; 1997 Mar; 16(3):268-74. PubMed ID: 9087869 [TBL] [Abstract][Full Text] [Related]
6. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
7. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517 [TBL] [Abstract][Full Text] [Related]
8. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients. Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041 [TBL] [Abstract][Full Text] [Related]
10. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050 [TBL] [Abstract][Full Text] [Related]
11. Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral. Sijpkens YW; Mallat MJ; Siegert CE; Zwinderman AH; Westendorp RG; de Fijter JW; van Es LA; Paul LC Clin Nephrol; 2001 Feb; 55(2):149-55. PubMed ID: 11269679 [TBL] [Abstract][Full Text] [Related]
12. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279 [TBL] [Abstract][Full Text] [Related]
14. [Conversion from +Sandimmune to Neoral in kidney transplant recipients treated with cyclosporine and ketoconazole]. Videla C; Vega J; Borja H; Gatica A; Clavero R; Aldunate T Rev Med Chil; 1997 Apr; 125(4):438-45. PubMed ID: 9460285 [TBL] [Abstract][Full Text] [Related]
15. Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year. Neumayer HH; Budde K; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC Clin Nephrol; 1996 May; 45(5):326-31. PubMed ID: 8738665 [TBL] [Abstract][Full Text] [Related]
16. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034 [TBL] [Abstract][Full Text] [Related]
17. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. Sharma A; Shekhar C; Heer M; Minz M Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996 [TBL] [Abstract][Full Text] [Related]
18. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy. Carstens J Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535 [TBL] [Abstract][Full Text] [Related]
19. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral. Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205 [TBL] [Abstract][Full Text] [Related]
20. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. Akhlaghi F; Gonzalez L; Trull AK J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]